Baxter licenses pathogen safety product to Haemonetics
This article was originally published in Clinica
Haemonetics is to pay up to $24.5 million to license the Intercept platelet system being developed jointly by Baxter International and Cerus to protect against the transmission of infectious diseases through platelet transfusion. As a result, Haemonetics will be able to "seamlessly integrate" its platelet collection devices with the Intercept platelet system.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.